Here are 1-3 brief analogies for OrthoPediatrics:

• Stryker for pediatric orthopedic devices.

• Johnson & Johnson's medical devices division, but focused entirely on children's orthopedic conditions.

• Medtronic, but dedicated solely to orthopedic implants and devices for children.

• PediLoc: An implant system used for trauma and deformity correction in children.
• PediPlates: Implants designed for treating various pediatric orthopedic conditions.
• Cannulated Screws: Surgical screws specifically used for bone fixation in pediatric patients.
• PediFlex Nail: A flexible intramedullary nail system for pediatric fractures.
• PediNail: A nailing system tailored for pediatric orthopedic procedures.
• PediLoc Tibia: A specialized PediLoc implant system specifically designed for the tibia.
• Anterior Cruciate Ligament Reconstruction Systems: Systems for repairing ACL injuries in children.
• Locking Cannulated Blades: Implants utilized for bone fixation in pediatric orthopedics.
• Locking Proximal Femurs: Implants designed for treating conditions of the proximal femur in children.
• Spica Tables: Surgical tables used during pediatric orthopedic procedures, often for hip conditions.
• RESPONSE Spine Systems: Comprehensive systems for treating spinal deformities, including scoliosis.
• Bandloc: A spinal implant utilized in scoliosis procedures.
• Pediguard: A spinal implant designed for treating spinal deformities.
• Pediatric Nailing Platform: A platform encompassing various products for pediatric bone nailing.
• Femur System: A system of implants and devices specifically for femur treatments in children.
• Orthex: An orthopedic implant or device for pediatric use.
• QuickPack: An orthopedic implant or device for pediatric use.
• ApiFix Mid-C System: A system for correcting spinal deformities, specifically in the mid-cervical region.

OrthoPediatrics (KIDS) sells its specialized orthopedic implants and devices primarily to healthcare institutions and medical professionals rather than directly to individuals. Its major customers fall into the following categories:

• Hospitals: These healthcare facilities are primary purchasers of medical devices, including OrthoPedoatrics' products, for use in pediatric orthopedic surgeries. The company serves the "pediatric orthopedic market," which largely comprises these institutions.
• Surgical Centers: Similar to hospitals, specialized surgical centers that perform orthopedic procedures on children are key customers, procuring the necessary implants and devices.
• Pediatric Orthopedic Surgeons: While the direct purchase may be made by the institutions, pediatric orthopedic surgeons are crucial customers as they are the end-users who select and specify which of OrthoPediatrics' products are used for their young patients. The company markets directly to these professionals.

David Bailey, President & CEO

David Bailey was appointed President and CEO of OrthoPediatrics effective June 1, 2021, and also serves as a Director on the Board. He joined the company in 2007 and has been instrumental in its growth from a start-up to a publicly traded entity, holding leadership positions in Domestic and International Sales, Operations, and overseeing the Trauma & Deformity Correction and Scoliosis business units. He played a key role in strategic agenda setting, capital raising, new product development, and establishing a global distribution network. Before joining OrthoPediatrics, he worked as a Sales Representative and Independent Distributor for Smith & Nephew Orthopaedics.

Fred Hite, Chief Financial Officer & Chief Operating Officer

Fred Hite joined OrthoPediatrics in February 2015 and also serves as a Director on the Board. Prior to OrthoPediatrics, he spent over ten years as the CFO and Investor Relations Officer of Symmetry Medical, a publicly traded company on the NYSE. During his time at Symmetry Medical, the company completed an Initial Public Offering (IPO), a secondary offering, and nine acquisitions. Before Symmetry Medical, Mr. Hite spent thirteen years with General Electric in a variety of financial positions.

Daniel Gerritzen, Executive Vice President (Legal) & General Counsel

Daniel Gerritzen has served as OrthoPediatrics' General Counsel since 2016.

Gregory Odle, President of Scoliosis

Gregory Odle joined OrthoPediatrics in 2007 and has held various leadership positions throughout the company's history, bringing 23 years of industry experience. Before OrthoPediatrics, he held various sales roles for Smith & Nephew, ultimately becoming District Manager for Indiana and Kentucky, where he achieved significant sales growth and led a team of 25 sales professionals.

Joe Hauser, President of Trauma, Deformity Correction and OPSB

Joe Hauser has 13 years of medical device experience, having held various leadership roles with DJO Global, Biomet (Trauma), and Zimmer (Trauma). He also pursued a Master's Degree in Business Administration with a Marketing focus from Capital University.

The key risks to OrthoPediatrics' business include its concentration in a niche market, its growth strategy heavily reliant on acquisitions with associated integration and asset impairment risks, and a notable reliance on debt financing.

1. Niche Market Concentration: OrthoPediatrics operates in the specialized pediatric orthopedics market. While this provides a dominant position within its niche, it inherently limits the company's overall addressable market and diversification opportunities. This focus means that the company's growth is largely tied to the expansion and dynamics of this specific segment of the healthcare industry.
2. Acquisition-Dependent Growth Strategy with Integration and Asset Impairment Risks: The company actively pursues acquisitions to drive growth. This strategy carries significant risks, including the challenges of successfully integrating acquired businesses and their operations. Furthermore, OrthoPediatrics' asset base, which includes substantial goodwill, intangible assets, and fixed assets, is subject to impairment, especially following acquisitions. The company recorded impairment charges in the third quarters of both 2023 and 2022.
3. Heavy Reliance on Debt Financing: OrthoPediatrics has demonstrated a heavy reliance on debt financing, including significant restructuring activity in 2024 such as terminating a credit facility and issuing $50 million in convertible notes. This reliance on debt, particularly with recent major refinancing efforts, represents a key financial risk to the company.

OrthoPediatrics (NASDAQ: KIDS) operates within the global pediatric orthopedic market, which it estimates to be approximately $6.2 billion.

Specifically, the addressable market in the United States for OrthoPediatrics' products is estimated at over $2.8 billion.

The company's main products and services address three key categories within this market: trauma and deformity, scoliosis, and sports medicine/other procedures.

Broader market reports on pediatric orthopedic devices indicate the global market size was estimated at USD 4.15 billion in 2024 and is projected to reach USD 7.78 billion by 2030, growing at a CAGR of 11.0% from 2025 to 2030. Another estimate places the global ortho pediatric devices market size at approximately USD 4.07 billion in 2024, predicted to grow to around USD 12.75 billion by 2035.

North America consistently holds a significant share of the pediatric orthopedic devices market, with revenue shares reported as 46.2% in 2023, 43.85% in 2025, and 41.7% in 2024.

OrthoPediatrics Corp. (KIDS) is expected to drive future revenue growth over the next 2-3 years through several key strategies:

1. Launch of New Products and Product Lines: The company is undergoing a multi-year "super cycle" of new product launches. The 3P Hip system is slated for a full commercial launch in 2026, with the 3P Small Mini in beta launch in 2026 and several new 3P systems planned over the next three years. Other new products include VerteGlide, eLLi, Playbook, IOTA Motion, PNP Retro, and a next-generation FD rod in telescopic nailing.
2. Expansion of OrthoPediatrics Specialty Bracing (OPSB) Business and Clinic Presence: The OPSB segment is projected to grow by over 20% annually for several years. OrthoPediatrics is actively expanding its clinic presence, particularly near children's hospitals, with the potential to serve up to 300 locations. This expansion strategy, including both new "greenfield" clinics and "acquihires," is ahead of schedule.
3. International Expansion and Global Commercial Reach: The company is leveraging its global commercial channels, with international revenue showing significant growth, including an 11% increase in Q1 2025 and 33% in Q4 2025. EU MDR approvals are crucial, allowing OrthoPediatrics to offer its full product line to European surgeons and creating market opportunities as competitors face compliance challenges. The acquisition of Folomed also aims to accelerate growth in Brazil.
4. Strategic Acquisitions: OrthoPediatrics' growth strategy includes selective mergers and acquisitions to expand its addressable market. The acquisition of Boston Orthotics & Prosthetics (O&P) is highlighted as a positive move, with an aggressive growth strategy planned for this integrated business.
5. Market Share Gains: The company emphasizes its leadership in pediatric orthopedics and its objective of taking market share across its business segments. This includes strategically utilizing previously deployed instrument sets to gain share in the surgical segment.

Share Repurchases

• In August 2024, OrthoPediatrics authorized a stock repurchase program for up to $5 million of its common stock.

Inbound Investments

• Squadron, a private investment firm, is the company's largest investor.
• In January 2024, OrthoPediatrics closed a debt financing agreement with MidCap Financial, providing up to $80 million through a term loan and revolving loan, which replaced a prior $50 million line of credit.

Outbound Investments

• In 2022, OrthoPediatrics acquired MD Ortho and Pega Medical. The Pega Medical acquisition was valued at $33 million, comprising $31 million in cash and $2 million in stock.
• In January 2024, the company acquired Boston Orthotics & Prosthetics (Boston O&P) for an upfront cash payment of $22 million, expanding its pediatric orthotic and prosthetic device offerings.
• In August 2025, OrthoPediatrics acquired C Prodirect, a manufacturer of medical devices for pediatric orthopedic conditions.

Capital Expenditures

• Capital expenditures totaled $17 million in 2025.
• For 2026, expected capital expenditures are projected to be $10 million.
• The primary focus of these expenditures is to increase investment in consigned implant and instrument sets and to expand the company's Orthotics & Prosthetics (O&P) clinic network.